Baylor College of Medicine

Use of Cytotoxic T-Lymphocytes for the Treatment of EBV, CMV, Adenovirus, and BK virus Infections (TETRAVI) (H-44843)



TETRAVI: Administration Of Most Closely HLA-Matched Multivirus-Specific Cytotoxic T-Lymphocytes For The Treatment Of EBV, CMV, Adenovirus, And BK Virus Infections Post Allogeneic Stem Cell Transplant

The purpose of this study is to use VSTs (virus-specific T cells) from a donor that is a partial HLA (human leukocyte antigen) match with the patient to treat viral infections after an allogeneic hematopoietic stem cell transplant (HSCT).

The patient must have had a myeloablative or non-myeloablative allogeneic HSCT using either bone marrow, single/double umbilical cord blood, or peripheral blood stem cells (PBSC). After a transplant, while the immune system grows back, the patient is at risk for infection. Some viruses can stay in the body for life and are normally controlled by a healthy immune system, but if the immune system is weakened, like after a transplant, they can cause life threatening infections. He/she must have had an infection with one or more of the following viruses -Epstein Barr virus (EBV), cytomegalovirus (CMV), adenovirus (AdV), Human polyomavirus type I (BKV), and human polyomavirus type II (JCV)- that has persisted or recurred despite standard therapy.

In this study, the investigators want to use white blood cells that have been trained to treat viral infections. In an earlier study the investigators showed that treatment with such specially trained T cells has been successful when the cells are made from the transplant donor. However as it takes 1-2 months to make the cells, that approach is not practical for patients who already have an infection. In a subsequent study, the investigators were able to create multivirus-specific T cells (VSTs) from the blood of healthy donors and created a bank of these cells. The investigators then successfully used these banked cells to treat virus infections after a stem cell transplant. In this study the investigators have further modified their production method to decrease the potential side effects and the investigators want to find out if they can use these banked VSTs to fight infections caused by the viruses mentioned above.

Age requirements: Child, adult, older adult (0-65+)

More information about this study can be found on

NCT#/ ID: NCT04013802


Kimberly McGee-Mooney

Phone 1: 832–275–0194

IRB: H-44843




Back to topback-to-top